GlassScriptPhysician profile
Audrey Joy Baute
NPI 1689194649
$3,149.05
in general payments reported to CMS, 2019-2025
23 companies · $1,367 in 2025
The $1,367 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $64.93 · 2023: $489 · 2024: $1,229 · 2025: $1,367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,084.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,084.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $707.06 | 2023-2025 | Vraylar |
| Novo Nordisk INC | $373.41 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $287.01 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $265.60 | 2022-2025 | Evenity, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $247.59 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Astellas Pharma US INC | $134.05 | 2024-2025 | Veozah |
| Abbott Laboratories | $132.67 | 2024-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $128.95 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $125.78 | 2023-2025 | |
| Glaxosmithkline, LLC. | $118.60 | 2022-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.39 | 2023-2025 | Jardiance |
| Neurocrine Biosciences, INC. | $102.43 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $91.42 | 2023-2025 | |
| Axsome Therapeutics, INC. | $60.34 | 2024 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $53.45 | 2024-2025 | Trintellix |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $38.14 | 2023-2024 | Gardasil 9, Vaxneuvance, Capvaxive |
| Idorsia Pharmaceuticals US INC | $37.92 | 2023 | Quviviq |
| Dynavax Technologies Corporation | $32.52 | 2023-2024 | Heplisav-B |
| Antares Pharma, INC. | $32.36 | 2023-2024 | Xyosted, Tlando, Nocdurna |
| Biohaven Pharmaceutical Holding Company LTD. | $28.12 | 2022 | |
| Lundbeck LLC | $18.44 | 2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $18.37 | 2025 | Hetlioz, Fanapt |
| Phathom Pharmaceuticals, INC. | $10.43 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Audrey Baute listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.